Rezolute Completes Enrollment in Phase 3 upLIFT Study; Topline Data Due Mid-December
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute has completed enrollment in the Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline results expected mid-December 2026. The primary endpoint is a 50% reduction in glucose infusion rate within 8 weeks. This follows the FDA's recent recommendation for a Type B pre-BLA meeting in congenital hyperinsulinism, indicating regulatory momentum. The company also plans to continue its expanded access program for compassionate use. Enrollment completion de-risks the timeline and sets a near-term catalyst for the stock.
At the time of this announcement, RZLT was trading at $4.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.2M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.